These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

182 related items for PubMed ID: 16981900

  • 1. Effect of multiple doses of montelukast on the pharmacokinetics of rosiglitazone, a CYP2C8 substrate, in humans.
    Kim KA, Park PW, Kim KR, Park JY.
    Br J Clin Pharmacol; 2007 Mar; 63(3):339-45. PubMed ID: 16981900
    [Abstract] [Full Text] [Related]

  • 2. Effect of quercetin on the pharmacokinetics of rosiglitazone, a CYP2C8 substrate, in healthy subjects.
    Kim KA, Park PW, Kim HK, Ha JM, Park JY.
    J Clin Pharmacol; 2005 Aug; 45(8):941-6. PubMed ID: 16027405
    [Abstract] [Full Text] [Related]

  • 3. Gemfibrozil markedly increases the plasma concentrations of montelukast: a previously unrecognized role for CYP2C8 in the metabolism of montelukast.
    Karonen T, Filppula A, Laitila J, Niemi M, Neuvonen PJ, Backman JT.
    Clin Pharmacol Ther; 2010 Aug; 88(2):223-30. PubMed ID: 20592724
    [Abstract] [Full Text] [Related]

  • 4. Effect of ketoconazole on the pharmacokinetics of rosiglitazone in healthy subjects.
    Park JY, Kim KA, Shin JG, Lee KY.
    Br J Clin Pharmacol; 2004 Oct; 58(4):397-402. PubMed ID: 15373932
    [Abstract] [Full Text] [Related]

  • 5. Effects of trimethoprim and rifampin on the pharmacokinetics of the cytochrome P450 2C8 substrate rosiglitazone.
    Niemi M, Backman JT, Neuvonen PJ.
    Clin Pharmacol Ther; 2004 Sep; 76(3):239-49. PubMed ID: 15371985
    [Abstract] [Full Text] [Related]

  • 6. Effects of laropiprant, a selective prostaglandin D(2) receptor 1 antagonist, on the pharmacokinetics of rosiglitazone.
    Schwartz JI, Stroh M, Gao B, Liu F, Rosko K, Zajic S, Meehan AJ, Ruckle J, Lai E, Wagner JA.
    Cardiovasc Ther; 2009 Sep; 27(4):239-45. PubMed ID: 19903187
    [Abstract] [Full Text] [Related]

  • 7. The effects of human CYP2C8 genotype and fluvoxamine on the pharmacokinetics of rosiglitazone in healthy subjects.
    Pedersen RS, Damkier P, Brosen K.
    Br J Clin Pharmacol; 2006 Dec; 62(6):682-9. PubMed ID: 16856883
    [Abstract] [Full Text] [Related]

  • 8. The targeted oral, once-daily phosphodiesterase 4 inhibitor roflumilast and the leukotriene receptor antagonist montelukast do not exhibit significant pharmacokinetic interactions.
    Böhmer GM, Nassr N, Wenger M, Hünnemeyer A, Lahu G, Templin S, Gleiter CH, Hermann R.
    J Clin Pharmacol; 2009 Apr; 49(4):389-97. PubMed ID: 19318692
    [Abstract] [Full Text] [Related]

  • 9. Multiple-dose administration of sitagliptin, a dipeptidyl peptidase-4 inhibitor, does not alter the single-dose pharmacokinetics of rosiglitazone in healthy subjects.
    Mistry GC, Bergman AJ, Luo WL, Cilissen C, Haazen W, Davies MJ, Gottesdiener KM, Wagner JA, Herman GA.
    J Clin Pharmacol; 2007 Feb; 47(2):159-64. PubMed ID: 17244766
    [Abstract] [Full Text] [Related]

  • 10. Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype.
    Kirchheiner J, Thomas S, Bauer S, Tomalik-Scharte D, Hering U, Doroshyenko O, Jetter A, Stehle S, Tsahuridu M, Meineke I, Brockmöller J, Fuhr U.
    Clin Pharmacol Ther; 2006 Dec; 80(6):657-67. PubMed ID: 17178266
    [Abstract] [Full Text] [Related]

  • 11. Montelukast pharmacokinetics in cystic fibrosis.
    Graff GR, Weber A, Wessler-Starman D, Smith AL.
    J Pediatr; 2003 Jan; 142(1):53-6. PubMed ID: 12520255
    [Abstract] [Full Text] [Related]

  • 12. Influence of cholestyramine on the pharmacokinetics of rosiglitazone and its metabolite, desmethylrosiglitazone, after oral and intravenous dosing of rosiglitazone: impact on oral bioavailability, absorption, and metabolic disposition in rats.
    Muzeeb S, Venkatesh P, Mullangi R, Srinivas NR.
    Xenobiotica; 2006 Sep; 36(9):838-56. PubMed ID: 16971347
    [Abstract] [Full Text] [Related]

  • 13. Rosiglitazone has no clinically significant effect on nifedipine pharmacokinetics.
    Harris RZ, Inglis AM, Miller AK, Thompson KA, Finnerty D, Patterson S, Jorkasky DK, Freed MI.
    J Clin Pharmacol; 1999 Nov; 39(11):1189-94. PubMed ID: 10579151
    [Abstract] [Full Text] [Related]

  • 14. Selective inhibition of human cytochrome P4502C8 by montelukast.
    Walsky RL, Obach RS, Gaman EA, Gleeson JP, Proctor WR.
    Drug Metab Dispos; 2005 Mar; 33(3):413-8. PubMed ID: 15608135
    [Abstract] [Full Text] [Related]

  • 15. Montelukast and zafirlukast do not affect the pharmacokinetics of the CYP2C8 substrate pioglitazone.
    Jaakkola T, Backman JT, Neuvonen M, Niemi M, Neuvonen PJ.
    Eur J Clin Pharmacol; 2006 Jul; 62(7):503-9. PubMed ID: 16670899
    [Abstract] [Full Text] [Related]

  • 16. Effect of citrus juice and SLCO2B1 genotype on the pharmacokinetics of montelukast.
    Mougey EB, Lang JE, Wen X, Lima JJ.
    J Clin Pharmacol; 2011 May; 51(5):751-60. PubMed ID: 20974993
    [Abstract] [Full Text] [Related]

  • 17. Effect of clarithromycin and fluconazole on the pharmacokinetics of montelukast in human volunteers.
    Hegazy SK, Mabrouk MM, Elsisi AE, Mansour NO.
    Eur J Clin Pharmacol; 2012 Sep; 68(9):1275-80. PubMed ID: 22392555
    [Abstract] [Full Text] [Related]

  • 18. Clopidogrel but Not Prasugrel Significantly Inhibits the CYP2C8-Mediated Metabolism of Montelukast in Humans.
    Itkonen MK, Tornio A, Filppula AM, Neuvonen M, Neuvonen PJ, Niemi M, Backman JT.
    Clin Pharmacol Ther; 2018 Sep; 104(3):495-504. PubMed ID: 29171020
    [Abstract] [Full Text] [Related]

  • 19. Trimethoprim and the CYP2C8*3 allele have opposite effects on the pharmacokinetics of pioglitazone.
    Tornio A, Niemi M, Neuvonen PJ, Backman JT.
    Drug Metab Dispos; 2008 Jan; 36(1):73-80. PubMed ID: 17913794
    [Abstract] [Full Text] [Related]

  • 20. Effect of montelukast on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers.
    Van Hecken A, Depré M, Verbesselt R, Wynants K, De Lepeleire I, Arnout J, Wong PH, Freeman A, Holland S, Gertz B, De Schepper PJ.
    J Clin Pharmacol; 1999 May; 39(5):495-500. PubMed ID: 10234597
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.